exoRehab and AI Digital Biomarker Neuromuscular Monitoring

EXOSYSTEMS is a Korean medical AI company based in Seongnam, Gyeonggi-do, that builds AI digital biomarkers from neuromuscular biosignals. It targets the reliance on expensive imaging, blood tests, needle-based exams and subjective performance tests when diagnosing and tracking sarcopenia, myasthenia gravis, stroke, Parkinson's disease and musculoskeletal disorders.

Skin-attached wearable sensors collect muscle signals that AI analyses in about three minutes to support diagnosis and severity assessment. The portfolio includes EXOMED-DeepSARC for sarcopenia diagnostic support, exoPill dynamic EMG for comparing affected and healthy sides after surgery, and exoRehab, an FDA-registered remote therapeutic monitoring (RTM) solution with a wearable sensor, mobile exercise app and web dashboard for clinicians. Customers include hospitals, rehabilitation clinics, pharma partners and wellness operators.

• AI digital biomarker: quantitative muscle biomarkers from neuromuscular biosignals measured by skin sensors.
• EXOMED-DeepSARC: AI sarcopenia diagnostic support designated an innovative medical device in Korea.
• exoPill dynamic EMG: compares affected and unaffected sides to track postoperative recovery.
• exoRehab RTM: wearable sensor plus mobile app delivering prescribed MSK exercises with compliance tracking.
• Clinician web dashboard: monitors MSK status of multiple patients with AI analysis.
• Patient engagement: real-time chat and reminders to improve exercise adherence.

Geriatric and rehabilitation departments in Vietnam could screen elderly patients for sarcopenia in minutes without imaging. Orthopaedic hospitals could track post-surgery recovery with dynamic EMG and continue home rehabilitation via exoRehab. Senior living operators and corporate wellness programmes could monitor muscle health of residents and employees.

Cuts labour-intensive neuromuscular assessments to an approximately 3-minute non-invasive process. Gives patients with limited mobility access to quantitative testing that conventional protocols cannot apply. Reduces examiner-dependent variability through standardised metrics. exoRehab lets US clinics bill remote therapeutic monitoring, with national average reimbursement of USD 19.38 for setup and USD 50.18 for device monitoring, while patients make fewer clinic visits.

Population ageing is raising sarcopenia, stroke and musculoskeletal disease burdens, while rehabilitation is shifting to home programmes with remote monitoring and reimbursement. Vietnam's population is ageing quickly and rehabilitation departments are short of therapists, creating demand for wearable tools that quantify recovery and support home exercise.

Headquartered in Seongnam, Gyeonggi-do, Korea. Won CES Innovation Awards for 2024 and 2026; minister's award at the Korea Invention Patent Exhibition (2023). AI sarcopenia diagnostic support designated an innovative medical device in Korea (2024). Partners include Daewoong Pharmaceutical, Seers Technology, K-MEDI hub and Abridge (exoFit). exoRehab is FDA registered.